Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study

Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study - Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049936

Enrollment

450

Registered

2022-12-29

Start date

2023-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with non-small cell lung cancer who have clinical stage III, IV or relapsed after radical treatment with surgery or radiotherapy according to the TNM classification, 8th edition 2) Patients who started CM227 or CM9LA or KN189 regimens as first-line therapy between December 1, 2018 and May 31, 2022

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
The efficacy (objective response rate, progression-free survival,and overall survival) and safety (adverse events, serious adverse events,and treatment-related death) of CM227 and CM9LA regimens	—

Countries

Japan

Contacts

Public ContactKinnosuke Matsumoto

Graduate School of Medicine, Osaka University Department of Respiratory Medicine and Clinical Immunology

m.kinnosuke@gmail.com06-6879-3831

Outcome results